15579060|t|Propofol: therapeutic indications and side-effects.
15579060|a|Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent which is widely used for the induction and maintenance of anesthesia and for sedation in the intensive care unit. Propofol is an oil at room temperature and insoluble in aqueous solution. Present formulations consists of 1% or 2% (w/v) propofol, 10% soybean oil, 2.25% glycerol, and 1.2% egg phosphatide. Disodium edetate (EDTA) or metabisulfite is added to retard bacterial and fungal growth. Propofol is a global central nervous system depressant. It directly activates GABA(A) receptors. In addition, propofol inhibits the NMDA receptor and modulates calcium influx through slow calcium ion channels. Propofol has a rapid onset of action with a dose-related hypnotic effect. Recovery is rapid even after prolonged use. Propofol decreases cerebral oxygen consumption, reduces intracranial pressure and has potent anti-convulsant properties. It is a potent antioxidant, has anti-inflammatory properties and is a bronchodilator. As a consequence of these properties propofol is being increasingly used in the management of traumatic head injury, status epilepticus, delirium tremens, status asthmaticus and in critically ill septic patients. Propofol has a remarkable safety profile. Dose dependent hypotension is the commonest complication; particularly in volume depleted patients. Hypertriglyceridemia and pancreatitis are uncommon complications. Allergic complications, which may include bronchospasm, have been reported with the formulation containing metabisulfite. In addition, this formulation has been demonstrated to result in the generation of oxygen free radicals. High dose propofol infusions have been associated with the "propofol syndrome"; this is a potentially fatal complication characterized by severe metabolic acidosis and circulatory collapse. This is a rare complication first reported in pediatric patients and believed to be due to decreased transmembrane electrical potential and alteration of electron transport across the inner mitochondrial membrane.
15579060	0	8	Propofol	Chemical	MESH:D015742
15579060	52	60	Propofol	Chemical	MESH:D015742
15579060	62	84	2, 6-diisopropylphenol	Chemical	MESH:D015742
15579060	239	247	Propofol	Chemical	MESH:D015742
15579060	254	257	oil	Chemical	MESH:D009821
15579060	361	369	propofol	Chemical	MESH:D015742
15579060	375	386	soybean oil	Chemical	MESH:D013024
15579060	394	402	glycerol	Chemical	MESH:D005990
15579060	417	428	phosphatide	Chemical	MESH:D010743
15579060	430	446	Disodium edetate	Chemical	MESH:D004492
15579060	448	452	EDTA	Chemical	MESH:D004492
15579060	457	470	metabisulfite	Chemical	MESH:C030981
15579060	504	510	fungal	Disease	MESH:D009181
15579060	519	527	Propofol	Chemical	MESH:D015742
15579060	629	637	propofol	Chemical	MESH:D015742
15579060	679	686	calcium	Chemical	MESH:D002118
15579060	729	737	Propofol	Chemical	MESH:D015742
15579060	847	855	Propofol	Chemical	MESH:D015742
15579060	875	881	oxygen	Chemical	MESH:D010100
15579060	1005	1017	inflammatory	Disease	MESH:D007249
15579060	1091	1099	propofol	Chemical	MESH:D015742
15579060	1148	1169	traumatic head injury	Disease	MESH:D006259
15579060	1171	1189	status epilepticus	Disease	MESH:D013226
15579060	1191	1207	delirium tremens	Disease	MESH:D000430
15579060	1209	1227	status asthmaticus	Disease	MESH:D013224
15579060	1246	1249	ill	Disease	MESH:D002908
15579060	1250	1256	septic	Disease	MESH:D001170
15579060	1257	1265	patients	Species	9606
15579060	1267	1275	Propofol	Chemical	MESH:D015742
15579060	1324	1335	hypotension	Disease	MESH:D007022
15579060	1399	1407	patients	Species	9606
15579060	1409	1429	Hypertriglyceridemia	Disease	MESH:D015228
15579060	1434	1446	pancreatitis	Disease	MESH:D010195
15579060	1475	1497	Allergic complications	Disease	MESH:D056486
15579060	1517	1529	bronchospasm	Disease	MESH:D001986
15579060	1582	1595	metabisulfite	Chemical	MESH:C030981
15579060	1680	1700	oxygen free radicals	Chemical	-
15579060	1712	1720	propofol	Chemical	MESH:D015742
15579060	1762	1770	propofol	Disease	MESH:D000072736
15579060	1847	1865	metabolic acidosis	Disease	MESH:D000138
15579060	1870	1890	circulatory collapse	Disease	MESH:D012769
15579060	1948	1956	patients	Species	9606
15579060	Positive_Correlation	MESH:D015742	MESH:D015228
15579060	Negative_Correlation	MESH:D015742	MESH:D013224
15579060	Negative_Correlation	MESH:D015742	MESH:D000430
15579060	Positive_Correlation	MESH:D015742	MESH:D007022
15579060	Negative_Correlation	MESH:C030981	MESH:D009181
15579060	Positive_Correlation	MESH:D015742	MESH:D000138
15579060	Positive_Correlation	MESH:D015742	MESH:D010195
15579060	Negative_Correlation	MESH:D010100	MESH:D015742
15579060	Positive_Correlation	MESH:C030981	MESH:D001986
15579060	Negative_Correlation	MESH:D015742	MESH:D001170
15579060	Negative_Correlation	MESH:D004492	MESH:D009181
15579060	Association	MESH:D002118	MESH:D015742
15579060	Positive_Correlation	MESH:D015742	MESH:D012769
15579060	Negative_Correlation	MESH:D015742	MESH:D002908
15579060	Positive_Correlation	MESH:D015742	MESH:D000072736
15579060	Positive_Correlation	MESH:C030981	MESH:D056486
15579060	Negative_Correlation	MESH:D015742	MESH:D006259
15579060	Negative_Correlation	MESH:D015742	MESH:D007249
15579060	Negative_Correlation	MESH:D015742	MESH:D013226

